Advertisement
U.S. Markets closed

Oragenics, Inc. (OGEN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Visitors trend2W10W9M
0.3260+0.0011 (+0.34%)
At close: 04:00PM EDT
0.3200 -0.01 (-1.84%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3249
Open0.3250
Bid0.3000 x 1000
Ask0.3250 x 2200
Day's Range0.3062 - 0.3450
52 Week Range0.2900 - 7.7400
Volume389,857
Avg. Volume773,426
Market Cap3.435M
Beta (5Y Monthly)0.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate

    On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002. What Happened: A recent study shows that the drug successfully targets areas inside the nose connected to the brain, making the drug more likely to reach and treat the brain after a concussion. In the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose.

  • Associated Press Finance

    Oragenics: Q2 Earnings Snapshot

    SARASOTA, Fla. AP) — Oragenics Inc. OGEN) on Friday reported a loss of $2.3 million in its second quarter.